
Coloplast is taking its first step into a new segment of the urology area. The medtech company has just made the final preparations for an extensive clinical study with the company's solution, a "tibial nerve stimulator," for over-active bladder disorder (OAB), the company reports in a press release.
"We will begin in the current quarter and expect the first results sometime during next year," President and CFO Anders Lonning-Skovgaard tells MedWatch.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers.
Start a free company trial todayMore from MedWatch
Fruergaard leveraging experience from Danish partnerships in key roles in Brussels
Experiences from Danish climate partnerships are among the tools that can be leveraged when Novo Nordisk CEO Lars Fruergaard begins stepping up efforts in the life science sector’s central organs in Brussels. ”I’ve been fired up by the intimacy and shared vision we could see in Denmark,” he tells MedWatch.